The rising prevalence of chronic diseases such as cancer is predicted to increase the incidence of hypercalcemia, fueling the growth of the worldwide hypercalcemia treatment market over the forecast period. The rising research and development efforts related to hypercalcemia treatment by the industry's leading players are likely to fuel the expansion of the worldwide hypercalcemia treatment market over the forecast period. Side effects of hypercalcemia medications are a key impediment to the growth of the global hypercalcemia therapy market. The rising adverse effects of medications used to treat hyperparathyroidism, the primary cause of hypercalcemia, are likely to stifle growth in the worldwide hypercalcemia treatment market over the forecast period.
According to Coherent Market Insights, the global Hypercalcemia Treatment Market is estimated to be valued at US$ 3,478.6 million in 2021, and is expected to exhibit a CAGR of 8.1% during the forecast period (2021-2028).
Key Competitors in the Hypercalcemia Treatment Industry:
1. Bayer AG
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. Founded in 1863, headquartered in Germany.
2. Pfizer, Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc.
3. Novartis AG
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. In January 2020, Novartis AG announced that it had completed acquisition of The Medicines Company, a pharmaceutical company. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.
4. Dr. Reddy’s Laboratories Ltd.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
5. Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. In August 2020, Amgen Inc. received the U.S. Food and Drug Administration (FDA) approval for the expansion of Kyprolis (Carfilzomib) in combination with Darzalex plus Dexamethasone in two dosing regimens for the treatment of relapsed multiple myeloma. In January 2020, Amgen Inc. and BeiGene announced strategic collaboration to expand its oncology presence in China. Moreover, Amgen Inc. collaborated with Guardant Health Inc. And Qiagen to accelerate the molecular testing for patients with Non-small Cell Lung Cancer.
6. Cipla Inc.
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company was incorporated in 1935 and is headquartered in Mumbai, India.
7. Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
8. Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company was incorporated in 1977 and is based in Mumbai, India.
9. Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
10. Slate Run Pharmaceuticals
Slate Run Pharmaceuticals LLC was founded in 2014. The company's line of business includes the wholesale distribution of prescription drugs, proprietary drugs, and toiletries. The company is headquartered in Columbus.
*Defintion- Hypercalcemia is a condition in which the calcium level in the blood is unusually high. Excess calcium in the blood can create kidney stones, weaken bones, and interfere with brain and heart function. The most prevalent cause of hypercalcemia is overactive parathyroid glands.
